Poster presentations: Clinical: Therapy and Observation 2022

P283 Infliximab re-challenge: could it be an option in refractory IBD patients?

P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratification

P285 Longitudinal single cell transcription profiling of peripheral blood disentangles shared and biologic-specific patterns of early remission in active IBD patients

P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open

P287 The knowledge and skills needed to perform intestinal ultrasound – An international Delphi consensus survey

P288 Recurrence rates of advanced neoplasia after endoscopic or surgical resection in Inflammatory Bowel Disease patients: a retrospective cohort study

P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project.

P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

P291 Effect of the preconception steroid-free remission period on disease activity during pregnancy and birth outcomes in women with Ulcerative Colitis: a retrospective cohort study

P292 Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis.

P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe

P294 On the way to disease control: Fatigue as part of a novel composite endpoint in an analysis of a prospective open label observation trial

P295 Proctitis during Crohn's disease, would it be a factor in the sustainability of anoperineal fistulas ?

P296 vedolizumab Does Not Increase Risk of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease Using vedolizumab: a Retrospective Cohort Study

P297 Treatment of patients with complex perianal Crohn's disease with darvadstrocel: a single-institution real life experience.

P298 Pregnancy in Crohn's and Colitis - Observations, Levels and Outcomes Extension (PICCOLO-X) Study: Biological therapy reduces faecal calprotectin and the need for corticosteroids in pregnant women with Inflammatory Bowel Disease

P299 Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baseline

P300 Very early onset Inflammatory Bowel Diseases: Review of the Genoa-Messina joint clinical experience. Therapeutic approach: Part II

P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease.

P302 Malignancy surveillance in patients with primary sclerosing cholangitis and Inflammatory Bowel Disease – keeping up with international guidelines? A Norwegian cohort study

P303 Biologic Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease: Are we aiming high?

P304 Intensified versus conventional infliximab induction in acute severe steroid-refractory Ulcerative Colitis

P305 Low ALT is more Common in Patients with IBD than Healthy Controls and is Associated with Active Disease

P306 Efficacy and tolerance of sodium picosulfate preparation in bowel Magnetic Resonance Imaging in Crohn’s disease

P307 The effect of COVID-19 infection and vaccination in patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome.

P308 Quadruple oral antibiotic treatment in refractory Paediatric Inflammatory Bowel Disease – incidence and analysis of responders from a 10 year cohort.

P309 Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort study

P310 Atopic dermatitis is associated with the clinical course of Inflammatory Bowel Disease

P311 Depression and anxiety are associated with poor clinical outcomes in Inflammatory Bowel Disease : A Nationwide Population-Based Study in South Korea

P312 Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial

P313 Within 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses

P314 Elderly onset is associated with low efficacy of anti-TNF treatment in Bio-naïve IBD patients: A multicenter cohort study by the Osaka Gut Forum

P315 High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study

P316 Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North

P317 Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn’s Disease

P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis

P319 Incorporating HLADQA1*05 in pre-biologic screening in IBD patients initiating biologic therapies

P320 6-Thioguanine nucleotide levels are associated with trough levels of infliximab and adalimumab in Inflammatory Bowel Disease patients on combination therapy: A retrospective multicentre study

P321 Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm study

P322 Effectiveness of Tumor Necrosis Factor-alpha inhibitors and Thiopurines combination therapy according to 6-thioguanine nucleotides plasma levels: A Systematic Review.

P323 The Crohn's Disease Exclusion Diet (CDED) for pouch inflammation: an interventional pilot study

P324 Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic review

P325 Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease

P326 The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease

P327 Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring

P328 In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease

P329 Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients

P330 Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination

P331 Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies

P332 Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).

P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach

P334 Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.

P335 Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with Biologics

P336 Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot study

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

P338 Early proactive drug monitoring strategy of infliximab as monotherapy for inflammatory bowel disease in paediatric patients is associated with good sustained clinical remission

P339 Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel Disease

P340 Risankizumab in Crohn's disease: Real World Experience from a Pre-Approval Access Program

P341 Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis – Analyses of induction and maintenance clinical trials

P342 Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium

P343 Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID

P344 What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis

P345 The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn’s Disease

P346 Chronic pouch failure rates after close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis.

P347 Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn’s disease

P348 Top down versus step-up strategies to prevent postoperative recurrence in Crohn’s disease

P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU).

P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.

P351 Allogenic adipose-derived mesenchymal stem cells (darvadstrocel) in Japanese patients with complex perianal fistulas in Crohn’s disease

P352 Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn’s disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study

P353 Agreement between patients, senior and junior physicians on disease activity and burden scoring in inflammatory bowel disease, using a tele-monitoring platform

P354 Immunological response to vaccination against SARS-COV-2 infection in Inflammatory Bowel Disease patients under immunosuppressive therapy: should we prioritize an additional booster injection?

P355 Exceeding treatment expectations in Crohn's disease: transmural healing and a new definition of deep remission

P356 Czech experience with treatment of Crohn´s disease perianal fistulas by allogenic mesenchymal stem cell

P357 Monitoring of Thiopurines and Methotrexate in Inflammatory Bowel Disease: Are we Monitoring Too Frequently? A Cross Sectional Study.

P358 Keeping it simple: How a streamlined referrals process reduces the time taken to initiate biologic therapy

P359 Radiomics could predict surgery at 10 years in Crohn’s disease

P360 The correlation between ophthalmological posterior segment findings and disease severity in patients with inflammatory bowel disease

P361 PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis

P362 Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.

P363 Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?

P364 Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprine

P365 Weight gain after initiation of adalimumab in patients with Crohn’s disease

P366 Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's Disease

P367 quality of life in patients with Inflammatory Bowel Disease

P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center

P369 Dual Biologic in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series

P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenance

P372 Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s disease

P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety

P374 Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulas

P375 Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients

P376 Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open

P379 Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?

P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease

P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis

P382 Novel Image Enhanced Endoscopy (IEE) technologies for surveillance of colonic Inflammatory Bowel Disease: A pilot study evaluating Texture and Colour Enhancement Imaging (TXI) and Linked Colour Imaging (LCI) as compared with chromoendoscopy.

P383 Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.

P384 Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

P385 Tailoring induction treatment for children with Crohn’s disease.

P386 Predictive models for assessing the response to ustekinumab in Crohn’s disease patients

P387 Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program

P388 Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic

P389 Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom

P390 Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn´s disease: multicentric experience in the Basque Country and Navarre

P391 Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy

P392 To study the prevalence of depression and anxiety in patients of Inflammatory Bowel Disease (IBD) and the efficacy of psychopharmacotherapy in these patients: A pilot study

P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis.

P394 A prospective analysis of body composition in patients with Inflammatory Bowel Disease and changes during biologic therapy

P395 Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab

P396 COVID-19 pandemic-related endoscopy delays did not translate to deleterious outcomes for patients with Inflammatory Bowel Disease: A retrospective cohort study

P397 Can upskilling pharmacy technicians support a robust and cost-effective Inflammatory Bowel Disease patient review process? A single-centre prospective study.

P398 Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study

P399 C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.

P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study

P401 Tofacitinib tissue exposure correlates with endoscopic outcome

P402 Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program

P403 The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.

P404 Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials

P405 Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project

P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates

P407 A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis

P408 Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis

P409 FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial

P410 safety of biological drugs for inflammatory bowel disease in elderly patients

P411 Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program

P412 Drug persistence and endoscopic, histologic and biochemical remission rates among patients following ileal pouch-anal anastomosis treated with biologic therapy: Results from a prospective patient cohort.

P413 Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE)

P414 Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity

P415 Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial

P416 Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease

P417 Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients

P418 Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease

P419 Long-term outcome of ulcerative colitis in pediatric patients who achieved mucosal and histological healing: a real-life referral center experience

P420 Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure

P421 Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn's disease

P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?

P423 Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.

P424 Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations

P425 Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy

P426 Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis

P427 Exploring phenotype and treatment of inflammatory bowel disease in the elderly

P428 A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysis

P429 Mesalazine has no place in the treatment of Crohn's disease. Really?

P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study

P431 Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial

P432 Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial

P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.

P434 The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease

P435 High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohort

P436 Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

P437 Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.

P438 The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.

P439 Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.

P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.

P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.

P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis

P443 Trough concentration response in infliximab and adalimumab treated children with IBD following treatment adjustment: A pharmacokinetic model.

P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort

P445 Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from Hungary

P446 Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s Proctitis

P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease

P448 Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis

P449 Autologous fat graft injection for the treatment of perianal fistulas in Crohn’s disease: A systematic review and single-arm meta-analysis

P450 Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease

P451 Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study

P452 Tofacitinib Effectiveness and Safety as Therapy for Ulcerative Colitis

P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease

P454 Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease

P455 Aminosalicylates in Ulcerative Colitis: old but gold?

P456 Risk of malignant tumors in patients with autoimmune diseases on ustekinumab therapy: a systematic review and meta-analysis

P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis

P458 Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn's disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN

P459 High inadequate surveillance rates in colitis-associated advanced neoplasia: a multicenter retrospective cohort study

P460 A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel Disease

P461 COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis

P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response

P463 Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity marker

P464 Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?

P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?

P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan

P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice

P468 Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study

P469 Infliximab for induction of medically-induced remission in Crohn's disease: a Cochrane systematic review

P470 Real-world characteristics and complications of patients with Ulcerative Colitis receiving conventional therapy in the public healthcare system in Brazil

P471 Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients

P472 Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysis

P473 Real world experience with the Crohn's Disease Exclusion Diet (CDED) in a tertiary IBD clinic

P474 Prevalence of fecal incontinence and clinical characteristics of IBD patients in remission and treated with biologics – experience from a tertiary referral center

P475 Profiling the use of Complementary Alternative Medicines among IBD patients

P476 Disease recurrence patterns in patients undergoing bowel resections for Crohn’s disease.

P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

P478 The role of proactive measurement of adalimumab trough levels and antibodies to adalimumab in Greek patients with Inflammatory Bowel Disease

P479 Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020

P480 Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitis

P481 profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease

P482 Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project

P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar

P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?

P485 Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease

P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials

P487 Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)

P488 Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®

P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.

P490 Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapy

P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE

P492 A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials

P493 The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study

P494 A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.

P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials

P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study

P497 Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis

P498 Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess: The Leeds Steroids study

P499 Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?

P500 The use of budesonide results in lower risk for infections compared to systemic glucocorticoids

P501 Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study

P502 Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China

P503 Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study

P504 Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease

P505 Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel Disease

P506 Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany

P507 Need for surgery in patients with ulcerative colitis in the era of biologic therapy.

P508 The impact of disease duration and early biologic treatment on transmural healing in Crohn’s disease

P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease

P510 Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysis

P511 Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapy

P512 Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s disease

P513 Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.

P514 Optimising response to infliximab in the management of perianal Crohn’s disease

P515 Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapy

P516 Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study

P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies

P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review

P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease

P520 Very early intestinal ultrasound predicts intravenous corticosteroid failure in hospitalized severe ulcerative colitis patients

P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenanc

P522 Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program

P523 effectiveness of biological treatments for inflammatory bowel disease in the elderly patients

P524 Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.

P525 A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study

P526 Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients

P527 Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)

P528 Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD

P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).

P530 Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis

P531 Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region

P532 Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels

[1] 2 > >>

ECCO'25 Abstracts

ECCO'24 Abstracts

Poster presentations: Clinical: Therapy and Observation 2022